Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15221MR)

This product GTTS-WQ15221MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFSF13&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001198622.2; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8741; 10673
UniProt ID Q2QBA2; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15221MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12912MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ3184MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ15145MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ9010MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ648MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ5740MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ1213MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ15715MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW